10x Genomics
146 hedge funds and large institutions have $5.45B invested in 10x Genomics in 2020 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 48 increasing their positions, 22 reducing their positions, and 21 closing their positions.
248% more call options, than puts
Call options by funds: $24.6M | Put options by funds: $7.06M
200% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 21
123% more capital invested
Capital invested by funds: $2.45B → $5.45B (+$3B)
118% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 22
40% more funds holding
Funds holding: 104 → 146 (+42)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
79.34% less ownership
Funds ownership: 184.68% → 105.34% (-79%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$311M |
| 2 |
Morgan Stanley
New York
|
+$247M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$224M |
| 4 |
1WCM
12 West Capital Management
New York
|
+$112M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$99.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$178M |
| 2 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$171M |
| 3 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$84.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$39.8M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$37.8M |
TXG Hedge Fund Activity: Q2 2020 in Review
146 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2020, worth a combined $5.45B — up 123% from $2.45B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new TXG positions and 21 closed out — a net gain of 42 holders — while 48 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $311M. The largest seller was Foresite Capital Management I, cutting an estimated $178M.
- 146 institutional investors held 10x Genomics (TXG) as of Q2 2020, up from 104 in Q1 2020.
- Funds reported $5.45B of 10x Genomics stock for Q2 2020, up 123% quarter-over-quarter.
- 63 funds opened new 10x Genomics positions in Q2 2020 and 21 closed out, a net change of +42 holders.
- The largest 10x Genomics buyer in Q2 2020 was Fidelity Investments, an estimated $311M added.
- The largest 10x Genomics seller in Q2 2020 was Foresite Capital Management I, an estimated $178M sold.
Based on aggregated 13F filings for Q2 2020.